Byooviz 10 MG/ML per 0.05 ML Injection

RxCUI: 2602359
RxNorm name: Byooviz 10 MG/ML per 0.05 ML Injection
Display name: Byooviz 10 MG/ML per 0.05 ML Injection
Full name: Byooviz 10 MG/ML per 0.05 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:25

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761202	Byooviz	ranibizumab-nuna	351(k) Interchangeable	Rx	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Byooviz	RANIBIZUMAB-NUNA	BIOGEN INC.	e46db299-edd1-4457-89b2-c1e2e505f1b0	2025-12-01	Warnings, Adverse reactions	Exact identifier rxcui: 2602359
Byooviz	RANIBIZUMAB-NUNA	Harrow Eye, LLC	77b53b2c-da0e-44b2-ade4-b08ff75a7584	2025-11-26	Warnings, Adverse reactions	Exact identifier rxcui: 2602359

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
e46db299-edd1-4457-89b2-c1e2e505f1b0	Byooviz 0.5 MG in 0.05 ML Injection [PSN] · 0.05 ML ranibizumab-nuna 10 MG/ML Injection [Byooviz] [SBD] · Byooviz 0.5 MG per 0.05 ML Injection [SY] · Byooviz 10 MG/ML per 0.05 ML Injection [SY]	4	14	These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a	20251201
77b53b2c-da0e-44b2-ade4-b08ff75a7584	Byooviz 0.5 MG in 0.05 ML Injection [PSN] · 0.05 ML ranibizumab-nuna 10 MG/ML Injection [Byooviz] [SBD] · Byooviz 0.5 MG per 0.05 ML Injection [SY] · Byooviz 10 MG/ML per 0.05 ML Injection [SY]	4	1	These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be	20251126